Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Dimeric 2G12 as a potent protection against HIV-1.

Luo XM, Lei MY, Feidi RA, West AP Jr, Balazs AB, Bjorkman PJ, Yang L, Baltimore D.

PLoS Pathog. 2010 Dec 16;6(12):e1001225. doi: 10.1371/journal.ppat.1001225.

2.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

3.

A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.

Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ.

AIDS. 2010 Jul 17;24(11):1633-40. Erratum in: AIDS. 2010 Oct 23;24(16):2601.

4.

Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.

Karpenko LI, Scherbakova NS, Chikaev AN, Tumanova OY, Lebedev LR, Shalamova LA, Pyankova OG, Ryzhikov AB, Ilyichev AA.

Mol Immunol. 2012 Apr;50(4):193-9. doi: 10.1016/j.molimm.2012.01.003. Epub 2012 Feb 15.

PMID:
22341130
5.

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.

Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, J├Ąger W, Jacobson J, Vetter N, Katinger H.

AIDS. 2002 Oct 18;16(15):2019-25.

PMID:
12370500
6.

Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

West AP Jr, Galimidi RP, Foglesong CP, Gnanapragasam PN, Huey-Tubman KE, Klein JS, Suzuki MD, Tiangco NE, Vielmetter J, Bjorkman PJ.

J Virol. 2009 Jan;83(1):98-104. doi: 10.1128/JVI.01564-08. Epub 2008 Oct 22.

8.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

9.
10.

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.

Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G.

AIDS. 2005 Nov 18;19(17):1957-66.

PMID:
16260901
11.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
14.
15.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

16.

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.

Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, VanCott T, Broder C, Polonis VR, Yu XF, Shao Y, Faix D, Valente P, Quinnan GV Jr.

J Virol. 2003 Mar;77(5):3119-30.

17.

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H.

J Virol. 2010 Jul;84(13):6645-53. doi: 10.1128/JVI.02339-09. Epub 2010 Apr 21.

18.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.

PMID:
16621193
19.

How antibodies block HIV infection: paths to an AIDS vaccine.

Putney S.

Trends Biochem Sci. 1992 May;17(5):191-6. Review.

PMID:
1350693
20.

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D.

Virology. 2007 Apr 10;360(2):294-304. Epub 2006 Nov 21.

Supplemental Content

Support Center